Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Year-end review for colon cancer device?:

This article was originally published in Clinica

Executive Summary

SpectraScience has said it is confident that the US FDA will review its premarket approval (PMA) application for the Optical Biopsy system for colorectal cancer later this year. The Minneapolis, Minnesota-based company met with the FDA in mid-July to discuss the PMA, which proposes the device's use as an adjunct to colonoscopy to avoid biopsy tissue removal. The next scheduled meeting of the FDA's gastroenterology and urology panel is November 18-19, the company pointed out.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel